Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FLOX
- Development stage
- Phase 4
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
FLOX is a chemotherapy regimen used primarily in the treatment of colorectal cancer. It is a combination of three drugs: oxaliplatin, 5-fluorouracil (5-FU), and leucovorin. Oxaliplatin is a platinum-based cytotoxic agent that forms DNA adducts, leading to DNA damage. 5-Fluorouracil is an antimetabolite that interferes with DNA and RNA synthesis, primarily by inhibiting thymidylate synthase. Leucovorin, a folinic acid derivative, enhances the cytotoxic effects of 5-FU.
- Brand names
- Eloxatin
- Other names
- Nordic FLOX
02
Targets
DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on FLOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FLOX.